Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 36 | 0 | 3 | 0 | €141.20 | €236.30 | 67.350% |
| Neurocrine Bioscience | 27 | 0 | 7 | 0 | €129.90 | €140.34 | 8.037% |
| Jazz Pharmaceuticals plc | 23 | 0 | 4 | 0 | €102.70 | €184.92 | 80.058% |
| Icon plc | 18 | 0 | 3 | 0 | €291.40 | €319.67 | 9.701% |
| Exelixis Inc. | 18 | 0 | 3 | 0 | €20.07 | €26.01 | 29.578% |
| United Therapeutics | 18 | 0 | 3 | 0 | €246.60 | €288.66 | 17.056% |
| Ultragenyx Pharmaceutical Inc. | 17 | 1 | 3 | 0 | €38.80 | €84.74 | 118.412% |
| Iovance Biotherapeutics Inc. | 19 | 3 | 0 | 0 | €12.38 | €25.20 | 103.577% |
| Halozyme Therapeutics Inc. | 14 | 0 | 3 | 0 | €39.08 | €50.33 | 28.794% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €151.00 | €184.76 | 22.358% |
| Medpace Holdings Inc | 9 | 0 | 3 | 0 | €366.00 | €421.61 | 15.193% |
| QIAGEN NV | 9 | 0 | 0 | 0 | €40.47 | €47.44 | 17.223% |
| Charles River Labs Intl | 9 | 0 | 0 | 0 | €212.20 | €247.61 | 16.686% |
| PTC Therapeutics Inc. | 14 | 5 | 3 | 0 | €28.40 | €41.51 | 46.171% |
| Xencor Inc. | 9 | 1 | 1 | 0 | €22.60 | €31.74 | 40.438% |
| Taro Pharmaceutical Industries Ltd | 8 | 0 | 2 | 0 | €39.40 | - | - |
| Horizon Pharma plc | 7 | 0 | 0 | 0 | €110.40 | - | - |
| MorphoSys AG | 7 | 0 | 0 | 0 | €66.90 | €65.00 | -2.840% |
| Agios Pharmaceuticals Inc. | 6 | 0 | 2 | 0 | €31.00 | €38.99 | 25.770% |
| Hutchison China MediTech Ltd ADR | 5 | 0 | 0 | 0 | €18.40 | €45.10 | 145.082% |
| Dr. Reddy's Laboratories Ltd. ADR | 6 | 1 | 1 | 0 | €67.00 | €74.65 | 11.411% |
| Canopy Growth Corp | 4 | 0 | 0 | 0 | €0.47 | €1.75 | 273.134% |
| Perrigo Co. plc | 3 | 0 | 0 | 0 | €28.68 | €35.99 | 25.472% |
| Nektar Therapeutics | 3 | 1 | 1 | 0 | €1.54 | €3.70 | 140.885% |
| Catalent Inc. | 2 | 0 | 0 | 0 | €52.56 | €55.00 | 4.642% |